Hookipa Pharma (NASDAQ:HOOK) Given Neutral Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a report released on Friday,Benzinga reports.

A number of other equities research analysts have also recently issued reports on the stock. JMP Securities cut their price objective on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research note on Thursday, November 21st. Royal Bank of Canada downgraded Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $48.00 to $2.00 in a report on Friday, December 20th.

Hookipa Pharma Price Performance

Shares of HOOK opened at $2.15 on Friday. Hookipa Pharma has a 1 year low of $1.75 and a 1 year high of $10.50. The stock has a 50 day simple moving average of $2.48 and a two-hundred day simple moving average of $4.11. The firm has a market cap of $25.92 million, a P/E ratio of -0.58 and a beta of 0.71.

Institutional Investors Weigh In On Hookipa Pharma

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its stake in shares of Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after acquiring an additional 108,844 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the period. Finally, Ikarian Capital LLC bought a new position in Hookipa Pharma during the 3rd quarter valued at approximately $228,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.